Understanding Metabolic Heterogeneity in Temporal Lobe Epilepsy

Drug-resistant temporal lobe epilepsy poses substantial clinical challenges for neurologists and neurosurgeons. Surgical resection remains the primary curative intervention for achieving seizure freedom in drug-refractory patients. Consequently, precise localization of the epileptogenic zone dictates long-term postoperative success. Clinicians routinely utilize 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) during presurgical evaluation to detect focal temporal hypometabolism. However, neuroimaging reveals striking phenotypic divergence across clinically similar patient cohorts. Some individuals display lateralized temporal hypometabolism (PET-positive), whereas others exhibit normometabolic profiles (PET-negative). Therefore, surgical planning becomes challenging when neuroimaging fails to reveal clear lateralization.

Historically, the biological mechanisms driving this metabolic discrepancy remained poorly understood. Researchers could not determine whether normometabolic patterns reflect milder pathology or distinct molecular pathophysiology. Moreover, macroscopic imaging cannot resolve microenvironmental biochemical changes within tissue. Advanced spatial omics technologies now bridge this diagnostic gap. By integrating lipid mass spectrometry imaging with quantitative microdissected proteomics, researchers can decipher the molecular architecture driving these phenotypes.

Spatial Lipidomics Reveals Distinct Phosphatidylserine Signatures

To resolve localized biochemical divergence, investigators utilized matrix-assisted laser desorption/ionization mass spectrometry imaging on surgical biopsies. The study evaluated neocortical and hippocampal tissues from PET-positive and PET-negative patients alongside nonepileptic controls. Consequently, this spatial modality mapped anatomical lipid distributions without compromising morphological tissue integrity. The resulting profiles uncovered pronounced differences in membrane phospholipid composition between patient subgroups.

Specifically, mass spectrometry imaging demonstrated a marked enrichment of phosphatidylserines within PET-positive specimens. Researchers detected this elevation across both neocortical gray matter and hippocampal subfields. Phosphatidylserines maintain membrane asymmetry, regulate synaptic vesicle fusion, and orchestrate apoptotic clearance. Furthermore, abnormal phosphatidylserine exposure modulates neuroinflammatory cascades and microglial activation. Therefore, selective phosphatidylserine accumulation in hypometabolic tissue suggests active membrane remodeling and cellular stress. Conversely, PET-negative specimens maintained phospholipid distributions resembling healthy control tissues. These lipidomic findings confirm that focal metabolic suppression correlates with structural membrane remodeling.

Proteomic Shifts and Calcium Signaling Dysregulation

Following lipid imaging, researchers performed laser capture microdissection on histology-annotated subregions. They isolated neocortical gray matter, hippocampal cornu ammonis, and the dentate gyrus for quantitative mass spectrometry. Subsequently, proteomic profiling uncovered profound expression disparities separating epileptic specimens from control brains. Both epilepsy cohorts displayed significant upregulation of pathways governing neuronal excitability and neurotransmitter transport. These shared molecular signatures corroborate the intrinsic hyper-synchrony characteristic of temporal lobe seizure networks.

However, comparative quantitative analysis between epileptic subtypes revealed critical molecular divergence. Most notably, PET-positive specimens displayed profound dysregulation across intracellular calcium signaling cascades compared to PET-negative specimens. Intracellular calcium homeostasis governs neurotransmitter release, synaptic plasticity, and neuronal survival. Chronic calcium overload triggers excitotoxic cascades and drives continuous seizure generation. In addition, perturbed calcium fluxes impair astrocyte-mediated glutamate clearance, perpetuating extracellular excitotoxicity. Consequently, marked calcium dysregulation explains why hypometabolic tissue exhibits heightened seizure propensity despite reduced glucose uptake. These observations establish calcium signaling as a primary driver of metabolic phenotype differentiation.

Regional Divergence Between Neocortical and Hippocampal Networks

The spatial proteomics workflow demonstrated that molecular alterations diverge significantly between neocortical and hippocampal compartments in PET-positive patients. In the neocortex of PET-positive individuals, proteomic pathways exhibited a striking metabolic transition. Specifically, cellular networks shifted from aerobic mitochondrial oxidative phosphorylation toward cytosolic metabolic processes. Mitochondria normally generate neuronal ATP required for repolarizing ion channels after action potentials. Consequently, this mitochondrial-to-cytosolic shift explains the focal glucose hypometabolism detected on presurgical FDG-PET scans. As oxidative efficiency declines, cortical neurons compensate by increasing cytosolic glycolysis, promoting energy failure during repeated seizures.

Conversely, the hippocampus of PET-positive patients presented a completely different constellation of biochemical abnormalities. Proteomic profiling demonstrated severe disruption of protein glycosylation pathways and polyamine metabolism. Disrupted glycosylation alters ion channel gating kinetics, impairs receptor trafficking, and weakens synaptic adhesion. Meanwhile, dysregulated polyamine metabolism impairs endogenous modulation of NMDA receptors and inward-rectifying potassium channels. Furthermore, polyamine imbalances compromise antioxidant defenses, leaving hippocampal subfields vulnerable to sustained oxidative injury. Thus, PET-positive temporal lobe epilepsy exhibits compartment-specific biochemical remodeling across distinct anatomical structures.

Translational Significance for Presurgical Evaluation and Stratification

These spatial omics discoveries carry immediate implications for epileptologists and neurosurgeons managing drug-resistant epilepsy. Clinicians frequently encounter diagnostic uncertainty when presurgical FDG-PET reveals normometabolic findings despite concordant electroclinical abnormalities. Traditionally, some centers considered PET-negative cases less optimal candidates for focal resection due to uncertain epileptogenic boundaries. However, these spatial multi-omic data prove that PET-negative epilepsy possesses authentic molecular pathology involving hyperactive excitatory transport. Therefore, clinicians should recognize that PET-negative status reflects metabolic preservation rather than an absence of epileptogenicity.

Furthermore, recognizing these biological subtypes enhances patient stratification during multidisciplinary epilepsy surgery conferences. Patients with PET-positive disease exhibit widespread mitochondrial collapse, calcium dysregulation, and profound membrane remodeling. Consequently, these individuals may require comprehensive resection margins to encompass biochemically vulnerable surrounding cortex. Conversely, PET-negative patients preserve mitochondrial integrity and normal lipid distributions, potentially favoring more selective surgical resections. In addition, integrating molecular signatures with functional neuroimaging refines non-invasive presurgical decision algorithms. By linking cellular biochemistry directly to macroscopic imaging phenotypes, surgical teams can better tailor individual operative strategies.

Future Directions in Precision Epileptology and Targeted Therapeutics

Current antiepileptic pharmacotherapy relies primarily on broad-spectrum ion channel blockers and GABA-enhancing agents. Unfortunately, nearly one-third of temporal lobe epilepsy patients develop intractable pharmacoresistance despite polytherapy. The identified subtype-specific molecular signatures offer tangible opportunities for developing targeted precision therapies. For example, stabilizing intracellular calcium dynamics represents an appealing therapeutic strategy specifically tailored for PET-positive patients. Novel small molecules targeting specific calcium channels or mitochondrial permeability transition pores could attenuate excitotoxicity without compromising healthy neurocircuitry.

Additionally, therapeutic interventions aimed at preserving mitochondrial respiration could rescue hypometabolic neocortical networks. Metabolic therapies, including modified ketogenic regimens or mitochondrial cofactors, might restore energy equilibrium in vulnerable cortical zones. Similarly, targeting polyamine synthesis or correcting hippocampal glycosylation pathways could mitigate epileptogenesis in severe mesial temporal sclerosis. In the future, minimally invasive liquid biopsies, such as cerebrospinal fluid extracellular vesicles, might detect these molecular signatures preoperatively. Ultimately, translating spatial omics into clinical epileptology will transform empirical treatment approaches into individualized, mechanism-driven therapies.

Frequently Asked Questions

What distinguishes PET-positive from PET-negative temporal lobe epilepsy?

PET-positive temporal lobe epilepsy exhibits localized temporal hypometabolism on fluorodeoxyglucose imaging, driven by mitochondrial failure and altered phosphatidylserine distribution. In contrast, PET-negative temporal lobe epilepsy demonstrates normometabolic activity on neuroimaging. Both subtypes show upregulated neuronal excitability pathways, but PET-negative tissue preserves mitochondrial respiration and membrane phospholipid organization.

How does spatial omics improve surgical evaluation in refractory epilepsy?

Spatial omics integrates mass spectrometry imaging and microdissected proteomics directly onto histological brain sections. Consequently, this technology maps localized molecular alterations within intact tissue architecture. This high-resolution approach elucidates the metabolic mechanisms underlying ambiguous PET imaging, helping multidisciplinary teams optimize surgical margins and stratify patients for epilepsy surgery.

Which molecular pathways represent promising targets for precision therapies?

Dysregulated intracellular calcium signaling and mitochondrial-to-cytosolic metabolic shifts represent primary therapeutic targets in PET-positive cases. In addition, hippocampal disruptions in polyamine metabolism and protein glycosylation provide actionable molecular pathways. Developing targeted pharmacological agents against these specific defects could suppress epileptogenesis and reverse drug resistance in refractory patients.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

Vermeulen I et al. Toward molecular phenotyping of temporal lobe epilepsy by spatial omics. Epilepsia. 2025 Jul. doi: 10.1111/epi.18366. PMID: 40110881.

Tenney JR, Rozhkov L, Horn P, Miles L, Miles MV. Cerebral glucose hypometabolism is associated with mitochondrial dysfunction in patients with intractable epilepsy and cortical dysplasia. Epilepsia. 2014;55(9):1415-1422. doi: 10.1111/epi.12731.

Ryvlin P, Rheims S. Predicting surgical outcome in temporal lobe epilepsy. Curr Opin Neurol. 2016;29(2):176-182. doi: 10.1097/WCO.0000000000000299.